PNU 282987
nAChR agonist / PNU 282987 is a selective α7 nicotinic acetylcholine receptor (nAChR) agonist (Ki = 26 nM).1 The α7 nAChR is a potential therapeutic target of cognitive deficits in diseases such as Alzheimers, Parkinsons, schizophrenia, and attention deficit disorders – agonism of this receptor with PNU 282987 has shown potential to ameliorate these deficits.2-5
Biochemicals & reagents
123464-89-1
1) Bodnar et al. (2005), Discovery and structure-activity relationship of quinuclidine benzamides as agonists of α7 nicotinic acetylcholine receptors; J. Med. Chem. 48 905 2) Stuckenholz et al. (2013), The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice; J. Parkinsons Dis. 3 161 3) Vicens et al. (2013), Motor and anxiety effects of PNU-282987, an alpha7 nicotinic receptor agonist, and stress in an animal model of Alzheimer’s disease; Curr. Alzheimer Res. 10 516 4) Navarro et al. (2015), Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase I induction; Biochem. Pharmacol. 97 473 5) McLean et al. (2016), Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders; Behav. Brain Res. 302 73
-20°C
TARGET: Acetylcholinesterase/Butyrylcholinesterase -- PATHWAY: ACh (Acetylcholine) signaling -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Neurodegeneration